142 related articles for article (PubMed ID: 36866993)
1. Meningococcemia in a vaccinated child receiving eculizumab and review of the literature.
Üçkardeş D; Göknar N; Kasap N; Keleşoğlu E; Arga M; Candan C
Turk J Pediatr; 2023; 65(1):129-134. PubMed ID: 36866993
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases.
Tanaka K; Fujita N; Hibino S
CEN Case Rep; 2020 Aug; 9(3):247-251. PubMed ID: 32240525
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.
Bozio CH; Isenhour C; McNamara LA
PLoS One; 2020; 15(11):e0241989. PubMed ID: 33180804
[TBL] [Abstract][Full Text] [Related]
4. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab.
Gäckler A; Kaulfuß M; Rohn H; Vogel U; Claus H; Feldkamp T; Kribben A; Witzke O
Nephrol Dial Transplant; 2020 Feb; 35(2):298-303. PubMed ID: 29992261
[TBL] [Abstract][Full Text] [Related]
5. Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome.
Cullinan N; Gorman KM; Riordan M; Waldron M; Goodship TH; Awan A
Pediatrics; 2015 Jun; 135(6):e1506-9. PubMed ID: 25941307
[TBL] [Abstract][Full Text] [Related]
6. Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab.
Polat M; Yüksel S; Şahin NÜ
Hum Vaccin Immunother; 2018; 14(11):2802. PubMed ID: 29883245
[No Abstract] [Full Text] [Related]
7. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
8. Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome.
Mülling N; Rohn H; Vogel U; Claus H; Wilde B; Eisenberger U; Kribben A; Witzke O; Gäckler A
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32159209
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab.
Parikh SR; Lucidarme J; Bingham C; Warwicker P; Goodship T; Borrow R; Ladhani SN
Pediatrics; 2017 Sep; 140(3):. PubMed ID: 28864711
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
11. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
13. Comparison of outcomes after plasma therapy or eculizumab in pediatric patients with atypical hemolytic uremic syndrome.
Ashida A; Matsumura H; Shimono A; Fujii Y; Yamazaki S
Clin Exp Nephrol; 2023 Feb; 27(2):161-170. PubMed ID: 36336723
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
[TBL] [Abstract][Full Text] [Related]
15. The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review.
de Souza RM; Correa BHM; Melo PHM; Pousa PA; de Mendonça TSC; Rodrigues LGC; Simões E Silva AC
Pediatr Nephrol; 2023 Jan; 38(1):61-75. PubMed ID: 35864223
[TBL] [Abstract][Full Text] [Related]
16. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
Tanaka K; Adams B; Aris AM; Fujita N; Ogawa M; Ortiz S; Vallee M; Greenbaum LA
Pediatr Nephrol; 2021 Apr; 36(4):889-898. PubMed ID: 33048203
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
[TBL] [Abstract][Full Text] [Related]
18. Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab.
Sharma S; Pradhan M; Meyers KE; Le Palma K; Laskin BL
Clin Nephrol; 2015 Sep; 84(3):181-5. PubMed ID: 25816809
[TBL] [Abstract][Full Text] [Related]
19. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
[TBL] [Abstract][Full Text] [Related]
20. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
